Dublin-based drug technology firm Merrion Pharmaceuticals said that it's encouraged by the continuing commitment of Danish group Novo Nordisk to bring an oral diabetes treatment to the market.
Merrion said that Novo Nordisk had completed the first phase of a study into its oral insulin product.
Merrion said the aim of the initial trial was to investigate the "safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect on blood glucose levels)" of the drug.
Last year Merrion, which has had a troubled recent past, said it was halting its own drug development programmes. It said it would focus on its relationship with Novo Nordisk after it failed to find a buyer for the firm.